# NCT03449381 (NCT03449381)

> This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03449381
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Boehringer Ingelheim
- Conditions: Neoplasms
- Interventions: BI 907828
- Enrollment: 266
- Primary outcome: Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycle
- Primary outcome: Phase Ib - Progression-free survival
- Primary outcome: Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B)
- Primary outcome: Phase Ib - Number of patients with DLTs during the first treatment cycle

## Indexed commentary on NCT03449381 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03449381